ASCO 2026 Lung Cancer is shaping up to be a major focus of this year’s meeting for thoracic oncology. In the OncoDaily Lung preview, the program is framed around 10 lung cancer trials to watch, spanning 4 confirmed and 6 anticipated presentations across NSCLC and SCLC. The overall theme is clear: ASCO 2026 Lung Cancer is expected to move beyond simple efficacy updates and into the more clinically important questions of durability, sequencing, CNS control, molecular selection, and first-line integration of new drug classes.
What makes this ASCO 2026 Lung Cancer lineup especially compelling is its breadth. There are mature survival updates in ALK-positive and EGFR-mutant NSCLC, next-generation targeted therapy signals in HER2-mutant and KRAS G12C disease, biomarker-agnostic ADC development in all-comers NSCLC, and potentially practice-changing first-line and maintenance strategies in small cell lung cancer. If several of these datasets deliver, ASCO 2026 Lung Cancer could become one of the most consequential recent meeting programs in thoracic oncology.
Why This ASCO 2026 Preview Matters
The thoracic oncology field is no longer asking whether targeted therapy or immunotherapy belongs in lung cancer. That question has already been answered. The real questions now are more refined. Which drug is best in first line? Which combinations are mature enough to replace current standards? Which subsets truly benefit from escalation? And where does biology, especially CNS activity and molecular subtype, begin to shape real treatment decisions?
That is exactly why this ASCO 2026 Lung Cancer article works so well as a preview. It captures not just the biggest names, but the actual pressure points in the field.
Four Confirmed Presentations Already Stand Out
The confirmed program begins with one of the most important long-term datasets in thoracic oncology: CROWN, the 7-year update of lorlatinib versus crizotinib in first-line ALK-positive NSCLC. The previous benchmark was already extraordinary, with 5-year progression-free survival of 60% versus 8%, a hazard ratio of 0.19, and median progression-free survival still not reached at five years. At ASCO 2026, the critical question is whether longer follow-up begins to clarify the overall survival story and whether lorlatinib’s position in frontline ALK disease becomes even more difficult to challenge.
The second confirmed presentation focuses on a high-need molecular space: frontline non-classical EGFR NSCLC with silevertinib (BDTX-1535). The prior dataset cited in the cards reported ORR 60%, CNS ORR 86%, and disease control rate 91%, while targeting more than 50 non-classical EGFR mutations, including exon 20 insertions. The update will likely be watched closely because this is exactly the kind of setting where durability matters as much as early activity. If duration of response and progression-free survival remain strong, silevertinib could become one of the most important emerging drugs in a space still lacking a clean frontline standard.
In small cell lung cancer, the confirmed IMforte subtype analysis adds a biological layer to a regimen that already showed efficacy. The combination of lurbinectedin plus atezolizumab previously produced PFS HR 0.54 and OS HR 0.73, and the regimen received FDA approval in October 2025. The ASCO 2026 question is different: which of the molecular SCLC subtypes, including SCLC-A, SCLC-N, SCLC-P, and SCLC-I, appears to drive the maintenance benefit? If a real subtype signal emerges, this would move the discussion beyond maintenance efficacy alone and toward a more selective strategy in SCLC.
The fourth confirmed presentation is a broader NSCLC platform story: sigvotatug vedotin plus pembrolizumab in advanced NSCLC. The featured ADC, SGN-B6A, targets IB6, which the carousel describes as expressed across NSCLC regardless of driver status. With phase III programs already enrolling, the question is whether updated ORR and duration of response support IB6 as a genuine biomarker-agnostic pan-NSCLC ADC target. That would be a major development because it would position this program not as a niche precision therapy, but as a potentially scalable platform across thoracic disease.
The Six Anticipated Presentations Could Still Steal the Meeting
The first of the anticipated presentations is MARIPOSA, which remains one of the most closely watched frontline EGFR studies. The trial comparing amivantamab plus lazertinib against osimertinib already showed a survival signal at ELCC 2025, with OS HR 0.75, median overall survival not reached versus 36.7 months, and an established PFS HR 0.70. One more year of follow-up now matures the curve further. At ASCO 2026, the real issue is whether the doublet’s maturing overall survival advantage becomes compelling enough to justify its added complexity over single-agent osimertinib.
You Can Read About MARIPOSA Trial on OncoDaily
The anticipated NeoADAURA update is another presentation with potentially broad implications. This trial evaluates neoadjuvant osimertinib with or without platinum-based chemotherapy in resectable EGFR-mutant NSCLC. Prior 2025 data cited in the carousel showed that osimertinib plus chemotherapy significantly increased major pathologic response compared with chemotherapy alone, and event-free survival data are now expected after more than twelve additional months of follow-up. The key clinical question is simple but important: does adding chemotherapy to neoadjuvant osimertinib create a meaningful event-free survival advantage, or is targeted therapy itself doing most of the work?
HER2 and KRAS Are Bringing New Sequencing Questions
One of the most interesting anticipated presentations is the Beamion LUNG-1 CNS cohort in HER2-mutant NSCLC. The study focuses on zongertinib, described in the carousel as a fourth-generation HER2 TKI, with FDA accelerated approval in February 2026 and prior systemic ORR 75%. The reason this presentation matters is not just overall activity but central nervous system performance. Since HER2-mutant NSCLC metastasizes intracranially in roughly 30% of patients, strong CNS data could materially affect sequencing against trastuzumab deruxtecan and other HER2-targeted strategies.
In KRAS G12C NSCLC, the anticipated SUNRAY-01 / LOXO-RAS-20001 presentation will examine olomorasib plus pembrolizumab in first-line disease. The prior Phase 1/2 dataset cited in the cards showed ORR 74% and disease control rate 91% in PD-L1-unselected first-line patients, alongside FDA Breakthrough Designation in September 2025. This makes it one of the most important first-line KRAS presentations expected in Chicago. The key issue at ASCO 2026 is whether the safety profile is strong enough to support olomorasib as a genuine contender for next KRAS G12C standard-setting therapy.
Small Cell Lung Cancer Could Be One of the Biggest Stories in Chicago
The anticipated DeLLphi-312 presentation may become one of the most discussed SCLC sessions of the meeting. The trial evaluates tarlatamab with or without durvalumab plus carboplatin/etoposide in first-line extensive-stage SCLC. The momentum behind it comes from DeLLphi-304, where the carousel cites OS HR 0.60, translating into a 40% reduction in risk of death versus chemotherapy, followed by FDA approval in November 2025. The ASCO 2026 question is whether tarlatamab-based combinations can be safely integrated into first-line treatment, especially with cytokine release syndrome management remaining central to implementation.
This is what makes the SCLC slate especially interesting. IMforte asks whether maintenance benefit can be biologically refined. DeLLphi-312 asks whether a DLL3 bispecific can move all the way into first line. Taken together, they represent a more ambitious SCLC agenda than the field had just a few years ago.
FLAURA2 Could Clarify Who Truly Needs Chemo in EGFR Disease
The final anticipated presentation in the carousel is FLAURA2 subgroup analyses, focused on osimertinib plus platinum-pemetrexed chemotherapy in first-line EGFR-mutated NSCLC. The prior overall survival update, cited from January 2026, showed OS HR 0.77, with 47.5 months versus 37.6 months. That already makes FLAURA2 important. What ASCO 2026 may add is clarity around who actually benefits most from the addition of chemotherapy. The cards specifically flag Ex19del versus L858R, brain metastasis subgroups, and post-progression management analyses. These are exactly the details clinicians need to decide whether chemo-osimertinib should be used broadly or selectively.
Read About FLAURA2 Trial on OncoDaily
The Real Themes of the Meeting
Taken together, these 10 studies show that thoracic oncology at ASCO 2026 will not be defined by one single topic. Instead, the meeting appears to be organized around several parallel themes.
One is maturity of benefit, seen in CROWN, MARIPOSA, and FLAURA2.
Another is expansion into difficult biologic spaces, seen in non-classical EGFR, HER2-mutant CNS disease, and KRAS G12C first line.
A third is earlier integration of new classes, particularly in SCLC with lurbinectedin maintenance biology and DLL3 bispecific movement into first-line treatment.
A fourth is the rise of broader-platform approaches, such as the IB6 ADC strategy that is being developed independent of classical driver subgroups.
These are not isolated stories. Together, they show a field moving from proof of concept to competitive refinement.
Which Presentations Could Be the Most Practice-Changing?
If the anticipated data are presented and remain strong, MARIPOSA, FLAURA2 subgroup analyses, and DeLLphi-312 may have the clearest chance to change clinical conversations immediately. CROWN may further cement rather than revolutionize current thinking, but its long-term maturity still matters enormously. Beamion LUNG-1 CNS data could become a sequencing-defining presentation in HER2-mutant NSCLC, while silevertinib may be one of the most important emerging-drug stories in a rarer EGFR subgroup.
The Bottom Line
The OncoDaily Lung ASCO 2026 article identifies a thoracic program built around 10 high-interest studies, including 4 confirmed and 6 anticipated presentations, across ALK, EGFR, HER2, KRAS, ADC development, and small cell lung cancer. The studies most likely to shape discussion in Chicago include CROWN, MARIPOSA, NeoADAURA, Beamion LUNG-1, SUNRAY-01, DeLLphi-312, and FLAURA2 subgroup analyses, each addressing a major unresolved question in current practice. If these datasets deliver, ASCO 2026 may become one of the most important recent meetings for lung cancer.